Coronary stents: A materials perspective

Biomaterials

Volumn 28, Issue 9, 2007, Pages 1689-1710

  Mani, Gopinath ^a   Feldman, Marc D ^b,c   Patel, Devang ^b   Agrawal, C Mauli ^a  

^a The University of Texas at San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Drug delivery; Stent; Surface modification; Surface treatment

Indexed keywords

BIOLOGICAL ORGANS; BIOMATERIALS; DRUG PRODUCTS; SURFACE TREATMENT;

CORONARY STENTS; DRUG DELIVERY; STENTS;

SURGICAL EQUIPMENT;

BIOMATERIAL; POLYMER;

CORONARY STENT; DRUG ELUTING STENT; HUMAN; MATERIAL COATING; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; REVIEW; SURFACE PROPERTY;

ALLOYS; ANIMALS; ANTICOAGULANTS; BLOOD VESSEL PROSTHESIS; COATED MATERIALS, BIOCOMPATIBLE; CORONARY VESSELS; DRUG IMPLANTS; HUMANS; PROSTHESIS DESIGN; STENTS;

EID: 33846171184     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2006.11.042     Document Type: Review

References (276)

1. Shepherd R.F.J., and Vlietstra R.E. The history of balloon angioplasty. In: Vlietstra R.E., and Holmes D.R. (Eds). Percutaneous transluminal coronary angioplasty (1987), F.A. Davis Company, Philadelphia 1-17
2. Myler R.K., and Stertzer S.H. Coronary and peripheral angioplasty: historical perspective. In: Topol E.J. (Ed). Textbook of interventional cardiology. 2nd ed (1994), W.B. Saunders Company, Philadelphia 171-185
3. Serruys P.W., Jaegere P.D., Kiemeneij F., Macaya C., Rutsch W., Heyndrickx G., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. New Engl J Med 331 8 (1994) 489-495
4. Fischman D.L., Leon M.B., Baim D.S., Schatz R.A., Savage M.P., Penn I., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. New Engl J Med 331 8 (1994) 496-501
5. Holmes J. State of the art in coronary intervention. Am J Cardiol 91 3A (2003) 50A-53A
6. Wolf M.G., Moliterno D., Lincoff A., and Topol E. Restenosis: an open file. Clin Cardiol 19 5 (1996) 347-356
7. Newby A.C., and Zaltsman A.B. Molecular mechanisms in intimal hyperplasia. J Pathol 190 (2000) 300-309
8. Mak K.H., Belli G., Ellis S.G., and Moliterno D.J. Subacute stent thrombosis: evolving issues and current concepts. JACC 27 2 (1996) 494-503
9. Kipshidze N., Dangas G., Tsapenko M., Moses J., Leon M.B., Kutryk M., et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J Am Coll Cardiol 44 4 (2004) 733-739
10. Ong A.T.L., McFadden E.P., Regar E., deJaegere P.P.T., vanDomburg R.T., and Serruys P.W. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 45 12 (2005) 2088-2092
11. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 293 17 (2005) 2126-2130
12. Taylor A. Metals. In: Sigwart U. (Ed). Endoluminal stenting (1996), W.B. Saunders Company Ltd, London 28-33
13. Schatz R.A. A view of vascular stents. Circulation 79 2 (1989) 445-457
14. Wong S.C., and Schatz R.A. Developmental background and design of the Palmaz-Schatz coronary stents. In: Herrmann Jr. H.C., and Hirshfeld J.W. (Eds). Clinical use of the Palmaz-Schatz intracoronary stent (1993), Futura Publishing Company, Inc., New York 3-19
15. Rundback J.H., Leonardo R., and Rozenbilt G.N. Peripheral vascular stents. In: Dolmatch B.L., and Blum U. (Eds). Stent-grafts current clinical practice (2000), Thieme, New York 1-22
16. Cardarelli F. Ferrous metals and their alloys. Materials handbook (2000), Springer London Limited, London 20-21
17. Haudrechy P., Foussereau J., Mantout B., and Baroux B. Nickel release from 304 and 316 stainless steels in synthetic sweat. Comparison with nickel and nickel-plated metals. Consequences on allergic contact dermatitis. Corros Sci 35 1-4 (1993) 329-336
18. Köster R., Sommerauer M., Kähler J., Baldus S., Meinertz T., Hamm C.W., et al. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet 356 9245 (2000) 1895-1897
19. Teitelbaum G., Bradley W., and Klein B. MR imaging artifacts, ferromagnetism, and magnetic torque of intravascular filters, stents, and coils. Radiology 166 3 (1988) 657-664
20. Hijazi Z., Homoud M., Aronovitz M., Smith J., and Faller G. A new platinum balloon-expandable stent (Angiostent) mounted on a high pressure balloon: acute and late results in an atherogenic swine model. J Invas Cardiol 7 5 (1995) 127-134
21. Bhargava B., Scheerder I.D., Ping Q., Yanming H., Chan R., Kim H.S., et al. A novel platinum-iridium, potentially gamma radioactive stent: evaluation in a porcine model. Cathet Cardiovasc Interv 51 3 (2000) 364-368
22. Trost D., Zhang H., Prince M., Winchester P., Wang Y., Watts R., et al. Three-dimensional MR angiography in imaging platinum alloy stents. J Magn Reson Imag 20 6 (2004) 975-980
23. Park J.B., and Kim Y.K. Metallic biomaterials. In: Park J.B., and Bronzino J.D. (Eds). Biomaterials principles and applications (2003), CRC Press, Boca Raton 1-20
24. Park J.B. Metallic implant materials. Biomater Sci Eng (1987), Plenum Press, New York 193-233
25. Foti R., Tamburino C., Galassi A., Russo G., Nicosia A., Grassi R., et al. Safety, feasibility and efficacy of a new single-wire stent in the treatment of complex coronary lesions: the angiostent. Cardiologia 43 7 (1998) 725-730
26. Zitter H., and Plenk H. The electrochemical behavior of metallic implant materials as an indicator of their biocompatibility. J Biomed Mater Res 21 7 (1987) 881-896
27. Johnson P., Bernstein J., Hunter G., Dawson W., and Hench L. An in vitro and in vivo analysis of anodized tantalum capacitive electrodes: corrosion response, physiology, and histology. J Biomed Mater Res 11 5 (1977) 637-656
28. Macionczyk F., Gerold B., and Thull R. Repassivating tantalum/tantalum oxide surface modification on stainless steel implants. Surf Coat Technol 142-144 (2001) 1084-1087
29. Teitelbaum G., Raney M., Carvlin M., Matsumoto A., and Barth K. Evaluation of ferromagnetism and magnetic resonance imaging artifacts of the Strecker tantalum vascular stent. Cardiovasc Intervent Radiol 12 3 (1989) 125-127
30. Matsumoto A., Teitelbaum G., Barth K., Carvlin M., Savin M., and Strecker E. Tantalum vascular stents: in vivo evaluation with MR imaging. Radiology 170 (1989) 753-755
31. Matsuno H., Yokoyama A., Watari F., Uo M., and Kawasaki T. Biocompatibility and osteogenesis of refractory metal implants, titanium, hafnium, niobium, tantalum and rhenium. Biomaterials 22 11 (2001) 1253-1262
32. Leng Y.X., Chen J.Y., Yang P., Sun H., Wang J., and Huang N. The biocompatibility of the tantalum and tantalum oxide films synthesized by pulse metal vacuum arc source deposition. Nucl Instrum Methods Phys Res Sec B: Beam Interact Mater Atoms 242 1-2 (2006) 30-32
33. 2 thin films. Biomaterials 23 12 (2002) 2545-2552
34. Chen J.Y., Leng Y.X., Zhang X., Yang P., Sun H., Wang J., et al. Effect of tantalum content of titanium oxide film fabricated by magnetron sputtering on the behavior of cultured human umbilical vein endothelial cells. Nucl Instrum Methods Phys Res Sec B: Beam Interact Mater Atoms 242 1-2 (2006) 26-29
35. Barth K., Virmani R., Froelich J., Takeda T., Lossef S., Newsome J., et al. Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and Wallstents in canine iliac and femoral arteries. Circulation 93 12 (1996) 2161-2169
36. Ozaki Y., Keane D., Nobuyoshi M., Hamasaki N., Popma J.J., and Serruys P.W. Coronary lumen at six-month follow-up of a new radiopaque cordis tantalum stent using quantitative angiography and intracoronary ultrasound. Am J Cardiol 76 16 (1995) 1103-1212
37. Davis J.R. Metallic materials. Handbook of medical devices (2003), ASM International, Materials Park 21-50
38. Windecker S., Mayer I., Pasquale G.D., Maier W., Dirsch O., Groot P.D., et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 104 8 (2001) 928-933
39. Mosseri M., Tamari I., Plich M., Hasin Y., Brizines M., Frimerman A., et al. Short- and long-term outcomes of the titanium-NO stent registry. Cardiovasc Revasc Med 6 1 (2005 2005) 2-6
40. Windecker S., Simon R., Lins M., Klauss V., Eberli F., Roffi M., et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 111 20 (2005) 2617-2622
41. Biehl V., Wack T., Winter S., Seyfert U., and Breme J. Evaluation of the haemocompatibility of titanium based biomaterials. Biomol Eng 19 2-6 (2002) 97-101
42. Sumita M., and Teoh S.H. Durability of metallic implant materials. In: Teoh S.H. (Ed). Engineering materials for biomedical applications (2004), World Scientific Publishing Co, Singapore 2-1-2-31
43. Stoeckel D., Pelton A., and Duerig T. Self-expanding nitinol stents: material and design considerations. Eur Radiol 14 2 (2004) 292-301
44. Trepanier C., Venugopalan R., and Pelton A.R. Corrosion resistance and biocompatibility of passivated NiTi. In: Yahia L.H. (Ed). Shape memory implants (2000), Springer, New York 35-45
45. Heintz C., Riepe G., Birken L., Kaiser E., Chakfe N., Morlock M., et al. Corroded nitinol wires in explanted aortic endografts: an important mechanism of failure?. J Endovasc Ther 8 3 (2001) 248-253
46. Berger-Gorbet M., Broxup B., Rivard C., and Yahia L. Biocompatibility testing of NiTi screws using immunohistochemistry on sections containing metallic implants. J Biomed Mater Res 32 2 (1996) 243-248
47. Shabalovskaya S. On the nature of the biocompatibility and on medical applications of NiTi shape memory and superelastic alloys. Biomed Mater Eng 6 4 (1996) 267-289
48. Maitz M., and Shevchenko N. Plasma-immersion ion-implanted nitinol surface with depressed nickel concentration for implants in blood. J Biomed Mater Res A 76 2 (2006) 356-365
49. O'Brien B., Carroll W., and Kelly M. Passivation of nitinol wire for vascular implants-a demonstration of the benefits. Biomaterials 23 8 (2002) 1739-1748
50. Trepanier C., Tabrizian M., Yahia L., Bilodeau L., and Piron D. Effect of modification of oxide layer on NiTi stent corrosion resistance. J Biomed Mater Res 43 4 (1998) 433-440
51. Mazumder M., De S., Trigwell S., Ali N., Mazumder M., and Mehta J. Corrosion resistance of polyurethane-coated nitinol cardiovascular stents. J Biomater Sci Polym Ed 14 12 (2003) 1351-1362
52. Starosvetsky D., and Gotman I. Corrosion behavior of titanium nitride coated Ni-Ti shape memory surgical alloy. Biomaterials 22 13 (2001) 1853-1859
53. Shih C., Lin S., Chung K., Chen Y., and Su Y. Increased corrosion resistance of stent materials by converting current surface film of polycrystalline oxide into amorphous oxide. J Biomed Mater Res 52 2 (2000) 323-332
54. Schurmann K., Vorwerk D., Kulisch A., Stroehmer-Kulisch E., Biesterfeld S., Stopinski T., et al. Experimental arterial stent placement. Comparison of a new nitinol stent and wallstent. Invest Radiol 30 7 (1995) 412-420
55. Adams G., Baltazar U., Karmonik C., Bordelon C., Lin P., Bush R., et al. Comparison of 15 different stents in superficial femoral arteries by high resolution MRI ex vivo and in vivo. J Magn Reson Imag 22 1 (2005) 125-135
56. Nakamura S., Degawa T., Nishida T., Anzai H., Mitsuo K., Sakatani H., et al. Preliminary experience of Act-One™ coronary stent implantation. J Am Coll Cardiol 27 2, Suppl. 1 (1996) 53
57. Holmes Jr. D.R., Lansky A., Kuntz R., Bell M.R., Buchbinder M., Fortuna R., et al. The PARAGON stent study: a randomized trial of a new martensitic nitinol stent versus the Palmaz-Schatz stent for treatment of complex native coronary arterial lesions. Am J Cardiol 86 10 (2000) 1073-1079
58. Isshiki T., Eto K., Ochini M., Milani H., Kondo K., Takoshita S., et al. Nitinol radius stent induces less platelet aggregation than stainless steel Palmaz-Schatz/Glanturco-Rubin II stents. J Am Coll Cardiol 31 Suppl. 1 (1998) 312
59. Brunski J.B. Metals. In: Ratner B.D., Hoffman A.S., Schoen F.J., and Lemons J.E. (Eds). Biomaterials science an introduction to materials in medicine. 2nd ed (2004), Elsevier Academic Press, San Diego 137-153
60. Briguori C., Sarais C., Pagnotta P., Liistro F., Montorfano M., Chieffo A., et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol 40 3 (2002) 403-409
61. Kastrati A., Mehilli J., Dirschinger J., Dotzer F., Schuhlen H., Neumann F.-J., et al. Intercoronary stenting and angiographic results: strut thickness effect on restenosis outcome. Circulation 103 23 (2001) 2816-2821
62. Rittersma S., Winter Rd., Koch K., Bax M., Schotborgh C., Mulder K., et al. Impact of strut thickness on late luminal loss after coronary artery stent placement. Am J Cardiol 93 4 (2004) 477-480
63. Kereiakes D., Cox D., Hermiller J., Midei M., Bachinsky W., Nukta E., et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 92 4 (2003) 463-466
64. Klocke A., Kemper J., Schulze D., Adam G., and Kahl-Nieke B. Magnetic field interactions of orthodontic wires during magnetic resonance imaging (MRI) at 1.5 Tesla. J Orofac Orthop 66 4 (2005) 279-287
65. US Food and Drug Administration, Center for Devices and Radiological Health, "MULTI-LINK VISION™ RX & OTW coronary stent system-P020047". Available from 〈http://www.fda.gov/cdrh/mda/docs/p020047.html〉 updated 16 September 2003.
66. Peuster M., Wohlsein P., Brügmann M., Ehlerding M., Seidler K., Fink C., et al. A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into new zealand white rabbits. Heart 86 5 (2001) 563-569
67. Heublein B., Rohde R., Kaese V., Niemeyer M., Hartung W., and Haverich A. Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?. Heart 89 6 (2003) 651-656
68. Peuster M., Hesse C., Schloo T., Fink C., Beerbaum P., and Schnakenburg Cv. Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. Biomaterials 27 28 (2006) 4955-4962
69. Mueller P.P., May T., Perz A., Hauser H., and Peuster M. Control of smooth muscle cell proliferation by ferrous iron. Biomaterials 27 10 (2006) 2193-2200
70. Staiger M., Pietak A., Huadmai J., and Dias G. Magnesium and its alloys as orthopedic biomaterials: a review. Biomaterials 27 9 (2006) 1728-1734
71. Cardarelli F. Less common non-ferrous metals. Materials handbook (2000), Springer London Limited, London 99-107
72. Busk R.S. Magnesium and its alloys. In: Kutz M. (Ed). Handbook of materials selection (2002), Wiley, New York 259-265
73. Eliezer D., and Alves H. Corrosion and oxidation of magnesium alloys. In: Kutz M. (Ed). Handbook of materials selection (2002), Wiley, New York 267-291
74. Mario C.D., Griffiths H., Goktekin O., Peeters N., Verbist J., Bosiers M., et al. Drug-eluting bioabsorbable magnesium stent. J Interv Cardiol 17 6 (2004) 391-395
75. Eggebrecht H., Rodermann J., Hunold P., Schmermund A., Bose D., Haude M., et al. Images in cardiovascular medicine. Novel magnetic resonance-compatible coronary stent: the absorbable magnesium-alloy stent. Circulation 112 18 (2005) e303-e304
76. Covino BS, Cramer SD. Corrosion: fundamentals, testing, and protection in ASM handbook, 10th ed. ASM International; 2003.
77. Zartner P., Cesnjevar R., Singer H., and Weyand M. First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby. Catheter Cardiovasc Interv 66 4 (2005) 595-596
78. Schranz D., Zartner P., Michel-Behnke I., and Akinturk H. Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn. Catheter Cardiovasc Interv 67 5 (2006) 671-673
79. Palmaz J. New advances in endovascular technology. Tex Heart Inst J 24 3 (1997) 156-159
80. Huang Y., Verbeken E., Schacht E., and Scheerder I.D. Local drug delivery using drug-eluting stents. In: Serruys P.W., Leon M.B., Colombo A., and Kutryk M.J. (Eds). Coronary lesions a pragmatic approach (2002), Martin Dunitz Ltd, London 319-335
81. Pypen C., Plenk H., Ebel M., Svagera R., and Wernisch J. Characterization of microblasted and reactive ion etched surfaces on the commercially pure metals niobium, tantalum and titanium. J Mater Sci Mater Med 8 12 (1997) 781-784
82. Ruckenstein E., and Gourisankar S.V. A surface energetic criterion of blood compatibility of foreign surfaces. J Colloid Interf Sci 101 2 (1984) 436-451
83. Bhat S.V. Synthetic polymers. Biomaterials. 2nd ed (2005), Alpha Science International Ltd, Harrow 64-65
84. Hamlin G., Rajah S., Crow M., and Kester R. Evaluation of the thrombogenic potential of three types of arterial graft studied in an artificial circulation. Br J Surg 65 4 (1978) 272-276
85. Fontaine A., Koelling K., Clay J., Spigos D., Passos S.D., Christoforidis G., et al. Decreased platelet adherence of polymer-coated tantalum stents. J Vasc Interv Radiol 5 4 (1994) 567-572
86. Scheerder I.D., Wilczek K., Verbeken E., Vandorpe J., Lan P., Schacht E., et al. Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. Atherosclerosis 114 1 (1995) 105-114
87. Wachem P.V., Vreriks C., Beugeling T., Feijen J., Bantjes A., Detmers J., et al. The influence of protein adsorption on interactions of cultured human endothelial cells with polymers. J Biomed Mater Res 21 6 (1987) 701-718
88. Budd J., Bell P., and James R. Attachment of indium-111 labelled endothelial cells to pretreated polytetrafluoroethylene vascular grafts. Br J Surg 76 12 (1989) 1259-1261
89. Knetsch M., Aldenhoff Y., Schraven M., and Koole L. Human endothelial cell attachment and proliferation on a novel vascular graft prototype. J Biomed Mater Res A 71 4 (2004) 615-624
90. Seeger J., Ingegno M., Bigatan E., Klingman N., Amery D., Widenhouse C., et al. Hydrophilic surface modification of metallic endoluminal stents. J Vasc Surg 22 3 (1995) 327-335
91. DePalma V.A., Baier R.E., Ford J.W., Gott V.L., and Furuse A. Investigation of three-surface properties of several metals and their relation to blood compatibility. J Biomed Mater Res 6 4 (1972) 37-75
92. Goldberg L., Bosco P., Shors E., Klein S., Nelson R., and White R. Effect of surface porosity on early thrombogenicity using vascular grafts with two surfaces in sequence. Trans Am Soc Artif Intern Organs 27 (1981) 517-521
93. Hecker J., and Scandrett L. Roughness and thrombogenicity of the outer surfaces of intravascular catheters. J Biomed Mater Res 19 4 (1985) 381-395
94. Zhao H., Humbeeck J.V., Sohier J., and Scheerder I.D. Electrochemical polishing of 316L stainless steel slotted tube coronary stents. J Mater Sci Mater Med 13 10 (2002) 911-916
95. Scheerder I.D., Sohier J., Wang K., Verbeken E., Zhou X.R., Frooyen L., et al. Metallic surface treatment using electrochemical polishing decreases thrombogenicity and neointimal hyperplasia after coronary stent implantation in a porcine model. JACC 31 Suppl. 1 (1998) 227A
96. Sheth S, Litvack F, Fishbein MC, Forrester JS, Eigler NL. Reduced thrombogenicity of polished and unpolished nitinol vs. stainless steel slotted-tube stents in a pig coronary artery model. JACC; 1996. Abstracts-Poster:197A.
97. Hehrlein C., Zimmermann M., Metz J., Ensinger W., and Kubler W. Influence of surface texture and charge on the biocompatibility of endovascular stents. Coron Artery Dis 6 7 (1995) 581-586
98. Palmaz J., Benson A., and Sprague E. Influence of surface topography on endothelialization of intravascular metallic material. J Vasc Interv Radiol 10 4 (1999) 439-444
99. Scott N.A., Robinson K.A., Nunes G.L., Thomas C.N., Viel K., King S.B., et al. Comparison of the thrombogenicity of stainless steel and tantalum coronary stents. Am Heart J 129 5 (1995) 866-872
100. Yahia L.H., and Ryhanen J. Bioperformance of shape memory alloys. In: Yahia L.H. (Ed). Shape memory implants (2000), Springer, New York 3-23
101. Gutensohn K., Beythien C., Bau J., Fenner T., Grewe P., Koester R., et al. In vitro analyses of diamond-like carbon coated stents: reduction of metal ion release, platelet activation, and thrombogenicity. Thromb Res 99 (2000) 577-585
102. Klien C.L., Kohler H., and Kirkpatrick C.J. Increased adhesion and activation of polymorphonuclear neutrophil granulocytes to endothelial cells under heavy metal exposure in vitro. Pathobiology 62 (1994) 90-98
103. Vogt P., Sigwart U., Urban P., Kaufmann U., Goy J., Stauffer J., et al. Immediate and late complications secondary to the implantation of a coronary endoprosthesis. Schweiz Med Wochenschr 119 43 (1989) 1521-1524
104. Giessen W.V.D., Serruys P., Woerkens L.V., Beatt K., Visser W., Jongkind J., et al. Arterial stenting with self-expandable and balloon-expandable endoprostheses. Int J Card Imag 5 2-3 (1990) 163-171
105. Strauss B., Serruys P., Bertrand M., Puel J., Meier B., Goy J., et al. Quantitative angiographic follow-up of the coronary wallstent in native vessels and bypass grafts (European experience-March 1986 to March 1990). Am J Cardiol 69 5 (1992) 475-481
106. Karas S., Gravanis M., Santoian E., Robinson K., Anderberg K., and King S. Coronary intimal proliferation after balloon injury and stenting in swine: an animal model of restenosis. J Am Coll Cardiol 20 2 (1992) 467-474
107. Ribeiro P., Gallo R., Antonius J., Mimish L., Sriram R., Bianchi S., et al. A new expandable intracoronary tantalum (Strecker) stent: early experimental results and follow-up to twelve months. Am Heart J 125 2 Pt 1 (1993) 501-510
108. Gunn J., and Cumberland D. Stent coatings and local drug delivery. Eur Heart J 20 (1999) 1693-1700
109. Hofma S. Recent developments in coated stents. Curr Intervent Cardiol Rep 3 (2001) 28-36
110. Liu C.L., Chu P.K., Lin G.Q., and Qi M. Anti-corrosion characteristics of nitride-coated AISI 316L stainless steel coronary stents. Surf Coat Technol 201 6 (2006) 2802-2806
111. Heldman A., Cheng L., Jenkins G., Heller P., Kim D., Ware M., et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103 18 (2001) 2289-2295
112. Nakayama Y., Ji-Youn K., Nishi S., Ueno H., and Matsuda T. Development of high-performance stent: gelatinous photogel-coated stent that permits drug delivery and gene transfer. J Biomed Mater Res 57 4 (2001) 559-566
113. Chen M., Liang H., Chiu Y., Chang Y., Wei H., and Sung H. A novel drug-eluting stent spray-coated with multi-layers of collagen and sirolimus. J Control Release 108 1 (2005) 178-189
114. Huang Y., Wang L., Verweire I., Qiang B., Liu X., Verbeken E., et al. Optimization of local methylprednisolone delivery to inhibit inflammatory reaction and neointimal hyperplasia of coated coronary stents. J Invasive Cardiol 14 9 (2002) 505-513
115. Huang N., Leng Y.X., Yang P., Chen J.Y., Sun H., Wang J., et al. Surface modification of coronary artery stent by Ti-O/Ti-N complex film coating prepared with plasma immersion ion implantation and deposition. Nucl Instrum Methods Phys Res Sec B: Beam Interact Mater Atoms 242 1-2 (2006) 18-21
116. Thierry B., Winnik F.M., Merhi Y., Silver J., and Tabrizian M. Radionuclides-hyaluronan-conjugate thromboresistant coatings to prevent in-stent restenosis. Biomaterials 25 17 (2004) 3895-3905
117. Herman R.A., Rybnikar A., Resch A., Marki B., Alt E., and Stemberger A. Thrombogenicity of stainless steel coronary stents with a completely gold coated surface. JACC Suppl. Feb (1998) 413A
118. Edelman E., Seifert P., Groothuis A., Morss A., Bornstein D., and Rogers C. Gold-coated NIR stents in porcine coronary arteries. Circulation 103 3 (2001) 429-434
119. Dahl J.R.V., Haager P.K., Grube E., Gross M., Beythien C., Kromer E.P., et al. Effects of gold coating of coronary stents on neointimal proliferation following stent implantation. Am J Cardiol 89 7 (2002) 801-805
120. Danzi G., Capuano C., Sesana M., Blasi A.D., Predolini S., and Antoniucci D. Patterns of in-stent restenosis after placement of NIR gold-coated stents in unselected patients. Catheter Cardiovasc Interv 55 2 (2002) 157-162
121. Seliger C., Schwennicke K., and Schaffar C. Influence of a rough, ceramic-like stent surface made of iridium oxide on neointimal structure and thickening. Eur Heart J 21 Suppl. (2000) 286
122. Sgura F., Mario C.D., Liistro F., Montorfano M., Colombo A., and Grube E. The lunar stent characteristics and clinical results. Herz 27 6 (2002) 514-517
123. Zhao Z.-H., Sakagami Y., and Osaka T. Toxicity of hydrogen peroxide produced by electroplated coatings to pathogenic bacteria. Can J Microbiol 44 5 (1998) 441-447
124. Mario C.D., Grube E., Nisanci Y., Reifart N., Colombo A., Rodermann J., et al. MOONLIGHT: a controlled registry of an iridium oxide-coated stent with angiographic follow-up. Int J Cardiol 95 2-3 (2004) 329-331
125. Bolz A., and Schaldach M. Artificial heart valves: improved blood compatibility by PECVD a-SiC:H coating. Artif Organs 14 4 (1990) 260-269
126. Unverdorben M., Sippel B., Degenhardt R., Sattler K., Fries R., Abt B., et al. Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir stent study's long-term outcome. Am Heart J 145 4 (2003) E17
127. Schuler P., Assefa D., Ylanne J., Basler N., Olschewski M., Ahrens I., et al. Adhesion of monocytes to medical steel as used for vascular stents is mediated by the integrin receptor Mac-1 (CD11b/CD18; alphaM beta2) and can be inhibited by semiconductor coating. Cell Commun Adhes 10 1 (2003) 17-26
128. Monnink S., Boven V., Peels, Tigchelaar, Kam D., Crijns, et al. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation. J Investig Med 47 6 (1999) 304-310
129. Kalnins U., Erglis A., Dinne I., Kumsars I., and Jegere S. Clinical outcomes of silicon carbide coated stents in patients with coronary artery disease. Med Sci Monit 8 2 (2002) 116-120
130. Tanajura LF, Abizaid AA, Feres F, Pinto I, Mattos L, Staico R, et al. Randomized intravascular ultrasound comparison between patients that underwent amorphous hydrogenated silicon-carbide coated stent deployment versus uncoated stent. JACC; 2003. Abstracts-Angiography & Interventional Cardiology:58A.
131. Unverdorben M., Sattler K., Degenhardt R., Fries R., Abt B., Wagner E., et al. Comparison of silicon carbide coated stent versus a noncoated stent in humans: the Tenax-versus Nir-stent Study. J Interv Cardiol 16 4 (2003) 325-333
132. Bickel C., Rupprecht H., Darius H., Binz C., Hauroder B., Krummenauer F., et al. Substantial reduction of platelet adhesion by heparin-coated stents. J Interv Cardiol 14 4 (2001) 407-413
133. Gutensohn K., Beythien C., Bau J., Fenner T., Grewe P., Koester R., et al. In vitro analyses of diamond-like carbon coated stents. Reduction of metal ion release, platelet activation, and thrombogenicity. Thromb Res 99 6 (2000) 577-585
134. Linder S., Pinkowski W., and Aepfelbacher M. Adhesion, cytoskeletal architecture and activation status of primary human macrophages on a diamond-like carbon coated surface. Biomaterials 23 3 (2002) 767-773
135. Antoniucci D., Bartorelli A., Valenti R., Montorsi P., Santoro G.M., Fabbiocchi F., et al. Clinical and angiographic outcome after coronary arterial stenting with the carbostent. Am J Cardiol 85 (2000) 821-825
136. Colombo A., and Airoldi F. Passive coating: the dream does not come true. J Invasive Cardiol 15 10 (2003) 566-567
137. Korkmaz M., Tayfun E., Muderrisoglu H., Yildirir A., Ozin B., Ulucam M., et al. Carbon coating of stents has no effect on inflammatory response to primary stent deployment. Angiology 53 5 (2002) 563-568
138. Airoldi F., Colombo A., Tavano D., Stankovic G., Klugmann S., Paolillo V., et al. Comparison of diamond-like carbon-coated stents versus uncoated stainless steel stents in coronary artery disease. Am J Cardiol 93 (2004) 474-477
139. Consigny P. Endothelial cell seeding on prosthetic surfaces. J Long Term Eff Med Implants 10 1-2 (2000) 79-95
140. Giessen W.V.D., Serruys P., and Visser W. Endothelialization of intravascular stents. J Interv Cardiol 1 (1988) 109-120
141. Doi K., and Matsuda T. Enhanced vascularization in a microporous polyurethane graft impregnated with basic fibroblast growth factor and heparin. J Biomed Mater Res 34 3 (1997) 361-370
142. Doi K., and Matsuda T. Significance of porosity and compliance of microporous, polyurethane-based microarterial vessel on neoarterial wall regeneration. J Biomed Mater Res 37 4 (1997) 573-584
143. Nakayama Y., Nishi S., Ishibashi-Ueda H., and Matsuda T. Surface microarchitectural design in biomedical applications: in vivo analysis of tissue ingrowth in excimer laser-directed micropored scaffold for cardiovascular tissue engineering. J Biomed Mater Res 51 3 (2000) 520-528
144. Nakayama Y., Nishi S., Ishibashi-Ueda H., Okamoto Y., and Nemoto Y. Development of microporous covered stents: geometrical design of the luminal surface. Int J Artif Organs 28 6 (2005) 600-608
145. Nakayama Y., Nishi S., and Ishibashi-Ueda H. Fabrication of drug-eluting covered stents with micropores and differential coating of heparin and FK506. Cardiovasc Radiat Med 4 2 (2003) 77-82
146. Wieneke H., Dirsch O., Sawitowski T., Gu Y., Brauer H., Dahmen U., et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv 60 3 (2003) 399-407
147. Kollum M., Farb A., Schreiber R., Terfera K., Arab A., Geist A., et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 64 1 (2005) 85-90
148. Peng T., Gibula P., Yao K., and Goosen M. Role of polymers in improving in improving the results of stenting in coronary arteries. Biomaterials 17 7 (1996) 685-694
149. Cooper S.L., Visser S.A., Hergenrother R.W., and Lamba N.M.K. Polymers. In: Ratner B.D., Hoffman A.S., Schoen F.J., and Lemons J.E. (Eds). Biomaterials science an introduction to materials in medicine. 2nd ed (2004), Elsevier Academic Press, San Diego 67-79
150. Giessen W.V.D., Slager C., Beusekom H.V., Schenau D.V.I., Huijts R., Schuurbiers J., et al. Development of a polymer endovascular prosthesis and its implantation in porcine arteries. J Interv Cardiol 5 3 (1992) 175-185
151. Davis J.R. Polymeric materials. Handbook of materials for medical devices (2003), ASM International, Materials Park 151-170
152. Murphy J.G., Schwartz R.S., Edwards W.D., Camrud A.R., Vlietstra R.E., and Holmer D.R. Percutaneous polymeric stents in porcine coronary artery initial experience with polyethylene terepthalate stents. Circulation 86 5 (1992) 1596-1604
153. Beusekom H.M.M.V., Giessen W.J.V.D., Schenau D.V.I., and Slager C.J. Synthetic polymers as an alternative to metal in stents? In vivo and mechanical behavior of polyethylene-terepthalate. Circulation 86 Suppl. 4 (1992) I-731 (Abstract # 2912)
154. Wilczek K.S.I., Wang K., Verbeken E., and Piessens J. Comparison of self-expanding polyethylene terephthalate and metallic stents implanted in porcine iliac arteries. Cardiovasc Intervent Radiol 19 3 (1996) 176-180
155. Tanguay J., Zidar J., Phillips H., and Stack R. Current status of biodegradable stents. Cardiol Clin 12 4 (1994) 699-713
156. Stack R., Califf R., Phillips H., Pryor D., Quigley P., Bauman R., et al. Interventional cardiac catheterization at Duke medical center. Am J Cardiol 62 (1988) 3F-24F
157. Agrawal C.M., Haas K.F., Leopold D.A., and Clark H.G. Evaluation of poly(l-lactic acid) as a material for intravascular polymeric stents. Biomaterials 13 3 (1992) 176-182
158. Lincoff A.M., Schwartz R.S., Giessen W.J.V.D., Beusekom H.M.M.V., Serruys P.W., Holmes D.R., et al. Biodegradable polymers can evoke a unique inflammatory response when implanted in the coronary artery. Circulation 86 Suppl.4 (1992) I-801 (Abstract # 3186)
159. Giessen W.V., Lincoff A., Schwartz R., Beusekom H.V., Serruys P., Holmes D., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94 7 (1996) 1690-1697
160. Lincoff A., Furst J., Ellis S., Tuch R., and Topol E. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 29 (1997) 808-816
161. Tamai H., Gaki K., Kyo E., Kosuga K., Kawashima A., Matsui S., et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 102 4 (2000) 399-404
162. Bar F., Veen F.V.D., and Benzina A. New biocompatible polymer surface coating for stents results in a low neointimal response. J Biomed Mater Res 52 (2000) 193-198
163. Edelman E., Adams D., and Karnovsky M. Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. Proc Natl Acad Sci 87 10 (1990) 3773-3777
164. Whelan D., Giessen W.V.D., Krabbendam S., Vliet E.V., Verdouw P., Serruys P., et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 83 (2000) 338-345
165. Banai S., Gertz S., Gavish L., Chorny M., Perez L., Lazarovichi G., et al. Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. Cardiovasc Res 64 1 (2004) 165-171
166. Tan L.P., Venkatraman S.S., Sung P.F., and Wang X.T. Effect of plasticization on heparin release from biodegradable matrices. Int J Pharm 283 (2004) 89-96
167. Venkatraman S., Tan L., Joso J., Boey Y., and Wang X. Biodegradable stents with elastic memory. Biomaterials 27 8 (2006) 1573-1578
168. Valimaa T., and Laaksovirta S. Degradation behaviour of self-reinforced 80L/20G PLGA devices in vitro. Biomaterials 25 7-8 (2004) 1225-1232
169. Talja M., Lumiaho J., Heino A., Alhava E., and Tormala P. Drainage and antireflux characteristics of a partial self-degradable self-expanding braided SR-PLGA ureteral stents. An experimental study. Eur Urol Suppl 3 2 (2004) 190
170. Severini A., Mantero S., Tanzi M., Cigada A., Addis F., Cozzi G., et al. In vivo study of polyurethane-coated Gianturco-Rosch biliary Z-stents. Cardiovasc Intervent Radiol 22 6 (1999) 510-514
171. Muller-Hulsbeck S., Walluscheck K., Priebe M., Grimm J., Cremer J., and Heller M. Experience on endothelial cell adhesion on vascular stents and stent-grafts: first in vitro results. Invest Radiol 37 6 (2002) 314-320
172. Lambert T., Dev V., Rechavia E., Forrester J., Litvack F., and Eigler N. Localized arterial wall drug delivery from a polymer-coated removable metallic stent. Kinetics, distribution, and bioactivity of forskolin. Circulation 90 2 (1994) 1003-1011
173. Dev V., Eigler N., Sheth S., Lambert T., Forrester J., and Litvack F. Kinetics of drug delivery to the arterial wall via polyurethane-coated removable nitinol stent: comparative study of two drugs. Cathet Cardiovasc Diagn 34 3 (1995) 272-278
174. Kondyurin A., Maitz M., Romanova V., Begishev V., Kondyurina I., and Guenzel R. Drug release from polyureaurethane coating modified by plasma immersion ion implantation. J Biomater Sci Polym Ed 15 2 (2004) 145-159
175. Rechavia E., Litvack F., Fishbien M., Nakamura M., and Eigler N. Biocompatibility of polyurethane-coated stents: tissue and vascular aspects. Cathet Cardiovasc Diagn 45 2 (1998) 202-207
176. Davis J.R. Handbook of medical devices (2003), ASM International, Materials Park
177. Park J.B. Soft tissue replacement implants. Biomaterials science and engineering (1987), Plenum Press, New York 338
178. Cumberland D., Gunn J., Malik N., and Holt C. Biomimicry 1: PC. Semin Interv Cardiol 3 3-4 (1998) 149-150
179. Whelan D., Giessen W.V.D., Krabbendam S., Vliet E.V., Verdouw P., Serruys P., et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. Heart 83 3 (2000) 338-345
180. Atalar E., Haznedaroglu I., Aytemir K., Aksoyek S., Ovunc K., Oto A., et al. Effects of stent coating on platelets and endothelial cells after intracoronary stent implantation. Clin Cardiol 24 2 (2001) 159-164
181. Grenadier E., Roguin A., Hertz I., Peled B., Boulos M., Nikolsky E., et al. Stenting very small coronary narrowings (<2 mm) using the biocompatible phosphoryline coated coronary stent. Catheter Cardiovasc Interv 55 3 (2002) 303-308
182. Galli M., Bartorelli A., Bedogni F., DeCesare N., Klugmann S., Maiello L., et al. Italian BiodivYsio open registry (BiodivYsio PC-coated stent): study of clinical outcomes of the implant of a PC-coated coronary stent. J Invas Cardiol 12 9 (2000) 452-458
183. Zheng H., Barragan P., Corcos T., Simeoni J., Favereau X., Roquebert P., et al. Clinical experience with a new biocompatible phosphorylcholine-coated coronary stent. J Invas Cardiology 11 10 (1999) 608-614
184. Lewis A., Tolhurst L., and Stratford P. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. Biomaterials 23 7 (2002) 1697-1706
185. Lewis A., Furze J., Small S., Robertson J., Higgins B., Taylor S., et al. Long-term stability of a coronary stent coating post-implantation. J Biomed Mater Res 63 6 (2002) 699-705
186. Lewis A., Willis S., Small S., Hunt S., O'byrne V., and Stratford P. Drug loading and elution from a phosphorylcholine polymer-coated coronary stent does not affect long-term stability of the coating in vivo. Biomed Mater Eng 14 4 (2004) 355-370
187. Lewis A., and Stratford P. Phosphorylcholine-coated stents. J Long Term Eff Med Implants 12 4 (2002) 231-250
188. Buellesfeld L., and Grube E. ABT-578-eluting stents. The promising successor of sirolimus- and paclitaxel-eluting stent concepts?. Herz 29 2 (2004) 167-170
189. Liu X., Huang Y., Hanet C., Vandormael M., Legrand V., Dens J., et al. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv 60 2 (2003) 172-178
190. Kwok O., Chow W., Law T., Chiu A., Ng W., Lam W., et al. First human experience with angiopeptin-eluting stent: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Catheter Cardiovasc Interv 66 4 (2005) 541-546
191. Verheye S., Markou C., Salame M., Wan B., King S., Robinson K., et al. Reduced thrombus formation by hyaluronic acid coating of endovascular devices. Arterioscler Thromb Vasc Biol 20 4 (2000) 1168-1172
192. Heublein B., Evagorou E., Rohde R., Ohse S., Meliss R., Barlach S., et al. Polymerized degradable hyaluronan-a platform for stent coating with inherent inhibiting effects on neointimal formation in a porcine coronary model. Int J Artif Organs 25 12 (2002) 1166-1173
193. Pitt W., Morris R., Mason M., Hall M., Luo Y., and Prestwich G. Attachment of hyaluronan to metallic surfaces. J Biomed Mater Res A 68 1 (2004) 95-106
194. Radosevich M., Goubran H., and Burnouf T. Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 72 3 (1997) 133-143
195. Weisel J.W. The mechanical properties of fibrin for basic scientists and clinicians. Biophys Chem 112 2-3 (2004) 267-276
196. Holmes D., Camrud A., Jorgenson M., Edwards W., and Schwartz R. Polymeric stenting in the porcine coronary artery model: differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 24 2 (1994) 525-531
197. McKenna CJ, Camrud AR, Sangiorgi G, Kwon HM, Edwards WD, Holmes DR, Jr. et al. Fibrin-film stenting in a porcine coronary injury model: Efficacy and safety compared with uncoated stents. JACC 1998;31(6):1434-1438.
198. Byer A., Peters S., Settepani F., Pagliaro M., and Galletti G. Fibrin sealant coated stents compared with non-coated stents in a porcine carotid artery model. Preliminary study report. J Cardiovasc Surg (Torino) 42 4 (2001) 543-549
199. Wilensky R.L., March K.L., Gradus-Pizlo I., Spaedy A.J., and Hathaway D.R. Methods and devices for local drug delivery in coronary and peripheral arteries. Trends Cardiovasc Med 3 5 (1993) 163-170
200. Hertzog B.A., Thanos C., Sandor M., Raman V., and Edelman E.R. Cardiovascular drug delivery systems. In: Mathiowitz E. (Ed). Encyclopedia of controlled drug delivery (1999), Wiley, New York 161-172
201. Kanellakopoulou K., and Giamarellos-Bourboulis E. Carrier systems for the local delivery of antibiotics in bone infections. Drugs 59 6 (2000) 1223-1232
202. Saito N., Murakami N., Takahashi J., Horiuchi H., Ota H., Kato H., et al. Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins. Adv Drug Deliv Rev 57 7 (2005) 1037-1048
203. Kimura H., and Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica 215 3 (2001) 143-155
204. Yasukawa T., Ogura Y., Kimura H., Sakurai E., and Tabata Y. Drug delivery from ocular implants. Expert Opin Drug Deliv 3 2 (2006) 261-273
205. Domb A., Maniar M., Bogdansky S., and Chasin M. Drug delivery to the brain using polymers. Crit Rev Ther Drug Carrier Syst 8 1 (1991) 1-17
206. Wang P., Frazier J., and Brem H. Local drug delivery to the brain. Adv Drug Deliv Rev 54 7 (2002) 987-1013
207. Tsuji T., Tamai H., Igaki K., Kyo E., Kosuga K., Hata T., et al. Biodegradable stents as a platform to drug loading. Int J Cardiovasc Intervent 5 1 (2003) 13-16
208. Day J.R.S., Landis R.C., and Taylor K.M. Heparin is much more than just an anticoagulant. J Cardiothor Vascu Anesth 18 1 (2004) 93-100
209. Hardhammar P., Beusekom H.V., Emanuelsson H., Hofma S., Albertsson P., Verdouw P., et al. Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries. Circulation 93 3 (1996) 423-430
210. Breckwoldt W., Belkin M., Gould K., Allen M., Connolly R., and Termin P. Modification of the thrombogenicity of a self-expanding vascular stent. J Invest Surg 4 3 (1991) 269-278
211. Grode G., Anderson S., Grotta H., and Falb R. Nonthrombogenic materials via a simple coating process. Trans Am Soc Artif Intern Organs 15 (1969) 1-6
212. Tanzawa H., Mori Y., Harumiya N., Miyama H., Hori M., Ohshima N., et al. Preparation and evaluation of a new athrombogenic heparinized hydrophilic polymer for use in cardiovascular system. Trans Am Soc Artif Intern Organs 19 (1973) 188-194
213. Larm O., Larssom R., and Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 11 2-3 (1983) 161-173
214. Labarre D., Jozefowicz M., and Boffa M.C. Properties of heparin-poly (methyl methacrylate) copolymers. J Biomed Mater Res 11 2 (1977) 283-295
215. Goosen M., and Sefton M. Properties of a heparin-poly(vinyl alcohol) hydrogel coating. J Biomed Mater Res 17 2 (1983) 359-373
216. Mazid M.A., Scott E., and Li N.-H. New biocompatible polyurethane-type copolymer with low molecular weight heparin. Clin Mater 8 1-2 (1991) 71-80
217. Yang Z., Birkenhauer P., Julmy F., Chickering D., Ranieri J., Merkle H., et al. Sustained release of heparin from polymeric particles for inhibition of human vascular smooth muscle cell proliferation. J Control Release 60 2-3 (1999) 269-277
218. Bonan R., Bhat K., Lefevre T., Lemarbre L., Paiement P., Wolff R., et al. Coronary artery stenting after angioplasty with self-expanding parallel wire metallic stents. Am Heart J 121 5 (1991) 1522-1530
219. Stratienko A., Zhu D., and Lambert C. Improved thromboresistance of heparin coated Palmaz-Schatz coronary stents in an animal model. Circulation 88 Abstracts (1993) I-596
220. Sheth S., Dev V., Jacobs H., Forrester J., Litvack F., and Eigler N. Prevention of subacute stent thrombosis by polymer-polyethylene oxide-heparin coating in the rabbit carotid artery. J Am Coll Cardiol 25 Abstracts (1995) 348A
221. Kiemeneij F., Serruys P., Macaya C., Rutsch W., Heyndrickx G., Albertsson P., et al. Continued benefit of coronary stenting versus balloon angioplasty: five-year clinical follow-up of Benestent-I trial. J Am Coll Cardiol 37 6 (2001) 1598-1603
222. Serruys P., Hout B.V., Bonnier H., Legrand V., Garcia E., Macaya C., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352 9129 (1998) 673-681
223. Stone G., Brodie B., Griffin J., Morice M., Costantini C., Goar F.S., et al. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary angioplasty in myocardial infarction stent pilot trial investigators. J Am Coll Cardiol 31 1 (1998) 23-30
224. Dzavik V., Carere R., Mancini G., Cohen E., Catellier D., Anderson T., et al. Predictors of improvement in left ventricular function after percutaneous revascularization of occluded coronary arteries: a report from the total occlusion study of Canada (TOSCA). Am Heart J 142 2 (2001) 301-308
225. Vrolix M., Legrand V., Reiber J., Grollier G., Schalij M., Brunel P., et al. Heparin-coated wiktor stents in human coronary arteries (MENTOR trial). MENTOR trial investigators. Am J Cardiol 86 4 (2000) 385-389
226. Matsumoto Y., Shimokawa H., Morishige K., Eto Y., and Takeshita A. Reduction in neointimal formation with a stent coated with multiple layers of releasable heparin in porcine coronary arteries. J Cardiovasc Pharmacol 39 4 (2002) 513-522
227. Marx S., Jayaraman T., Go L., and Marks A. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circul Res 76 3 (1995) 412-417
228. Poon M., Marx S., Gallo R., Badimon J., Taubman M., and Marks A. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 10 (1996) 2277-2283
229. Kipshidze N., Leon M., Tsapenko M., Falotico R., Kopia G., and Moses J. Update on sirolimus drug-eluting stents. Curr Pharm Des 10 4 (2004) 337-348
230. US Food and Drug Administration; Center for Devices and Radiological Health, "CYPHER™ Sirolimus-eluting coronary stent-P020026". Available from 〈http://www.fda.gov/cdrh/mda/docs/p020026.html〉 updated 10 June 2003.
231. Schampaert E., Cohen E.A., Schluter M., Reeves F., Traboulsi M., Title L.M., et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43 6 (2004) 1110-1115
232. Moussa I., Leon M., and Baim D. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS substudy. Circulation 109 (2004) 2273-2278
233. Morice M.-C., Serruys P., and Costantini C. Three-year follow-up of the RAVEL study: a randomized study with the Sirolimus-eluting Bx VelocityTM stent in the treatment of patients with De Novo native coronary lesions. JACC 43 5; Suppl. 1 (2004) 87A-88A
234. Schofer J., Schluter M., and Gershlick A. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
235. Wijns W. The European multicenter, randomized, double-blind study of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions (E-SIRIUS): 1-year clinical outcomes. Eur Heart J 24 5 Suppl 1 (2003) 267
236. Liistro F., and Bolognese L. Drug-eluting stents. Heart Drug 3 (2003) 203-213
237. Katuza G.L., Gershlick A.H., Park S.-J., Scheerder I.D., Chevalier B., Camenzind E., et al. Comparison of neointimal formation in polymer-free paclitaxel stents versus stainless steel stents from the ASPECT and ELUTES randomized clinical trial. Am J Cardiol 94 (2004) 199-201
238. Gershlick A., Scheerder I., and Chevalier B. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaluation of paclitaxel eluting stent (ELUTES) trial. Circulation 109 (2004) 487-493
239. 2™ Coronary Stent System (P030025); Summary of safety and effectiveness data. 〈http://wwwfdagov/cdrh/pdf3/P030025bpdf〉 〈http://wwwfdagov/ohrms/dockets/dailys/04/sep04/090904/04m-0403-aav0001-03-SSED-vol1pdf〉 2003.
240. Ranade S., Miller K., Richard R., Chan A., Allen M., and Helmus M. Physical characterization of controlled release of paclitaxel from the TAXUS Express2 drug-eluting stent. J Biomed Mater Res A 71 4 (2004) 625-634
241. Sipos L., Som A., Faust R., Richard R., Schwarz M., Ranade S., et al. Controlled delivery of paclitaxel from stent coatings using poly(hydroxystyrene-b-isobutylene-b-hydroxystyrene) and its acetylated derivative. Biomacromolecules 6 5 (2005) 2570-2582
242. Finci L., Silber S., Grube E., and Belardi J. Paclitaxel-eluting stent in complicated lesions of patient subsets: a subanalysis from the TAXUS II study. JACC 43 5; Suppl. 1 (2004) 46A
243. Drachman D.E. Clinical experience with drug-eluting Stents. Rev Cardiovasc Med 3 Suppl. 5 (2002) S31-S37
244. Stone G., Ellis S., Cox D., Hermiller J., O'Shaughnessy C., Mann J., et al. One-year clinical results with slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 16 (2004) 1942-1947
245. Kastrati A., Dibra A., Eberle S., Mehilli J., Lezo J.S.D., Goy J.-J., et al. Sirolimus-eluting stents vs Paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
246. Creel C., Lovich M., and Edelman E. Arterial paclitaxel distribution and deposition. Circ Res 86 8 (2000) 879-884
247. Lovich M., and Edelman E. Mechanisms of transmural heparin transport in the rat abdominal aorta after local vascular delivery. Circ Res 77 6 (1995) 1143-1150
248. Hwang C., Wu D., and Edelman E. Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Intervent 5 1 (2003) 7-12
249. Ong A.T.L., Hoye A., Aoki J., vanMieghem C.A., Granillo G.A.R., Sonnenschein K., et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 45 6 (2005) 947-953
250. Heller L.I., Shemwell K.C., and Hug K. Late stent thrombosis in the absence of prior intracoronary brachytherapy. Catheter Cardiovasc Interv 53 1 (2001) 23-28
251. Wang F., Stouffer G., Waxman S., and Uretsky B. Late coronary stent thrombosis: early vs. late stent thrombosis in the stent era. Catheter Cardiovasc Interv 55 2 (2002) 142-147
252. McFadden E.P., Stabile E., Regar E., Cheneau E., Ong A.T.L., Kinnaird T., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 9444 (2004) 1519-1521
253. Joner M., Finn A., Farb A., Mont E., Kolodgie F., Ladich E., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 1 (2006) 203-205
254. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 6 (2004) 701-705
255. Ong A.T.L., and Serruys P.W. Drug-eluting stents: current issues. Tex Heart Inst J 32 3 (2005) 372-377
256. Moreno R., Fernandez C., Hernandez R., Alfonso F., Angiolillo D.J., Sabate M., et al. Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 45 6 (2005) 954-959
257. Mauri L., O'Malley A.J., Cutlip D.E., Ho K.K., Popma J.J., Chauhan M.S., et al. Effects of stent length and lesion length on coronary restenosis. Am J Cardiol 93 11 (2004) 1340-1346
258. Chieffo A., Bonizzoni E., Orlic D., Stankovic G., Rogacka R., Airoldi F., et al. Intraprocedural stent thrombosis during implantation of sirolimus-eluting stents. Circulation 109 22 (2004) 2732-2736
259. Fujii K., Carlier S.G., Mintz G.S., Yang Y.-M., Moussa I., Weisz G., et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study. J Am Coll Cardiol 45 7 (2005) 995-998
260. Virmani R., Farb A., Guagliumi G., and Kolodgie F. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 15 6 (2004) 313-318
261. Virmani R., Kolodgie F., and Farb A. Drug-eluting stents: are they really safe?. Am Heart Hosp J 2 2 (2004) 85-88
262. Nebeker J.R., Virmani R., Bennet C.L., Hoffman J.M., Samore M.H., Alvarez J., et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 47 1 (2006) 182-183
263. McFadden E., Stabile E., Regar E., Cheneau E., Ong A., Kinnaird T., et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364 (2004) 1466-1467
264. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 17 (2005) 2154-2156
265. Mani G., Mahapatro A., Johnson D.M., Patel D.N., Feldman M.D., Ayon A.A., et al. Therapeutic self-assembled monolayers (2005), Biomedical Engineering Society, Baltimore, MD Abstract no: 652
266. Mahapatro A., Johnson D.M., Patel D.N., Feldman M.D., Ayon A.A., and Agrawal C.M. Surface modification of functional self-assembled monolayers on 316L stainless steel via lipase catalysis. Langmuir 22 3 (2006) 901-905
267. Mani G, Johnson DM, Marton D, Mahapatro A, Feldman M, Patel D, et al. Drug elution using self-assembled monolayers. In: Transactions of the 31st annual meeting of the Society For Biomaterials. Society For Biomaterials, Pittsburgh, PA, USA; 2006. Abstract no: 307.
268. Mani G, Johnson DM, Marton D, Mahapatro A, Feldman M, Patel D, et al. Stability of therapeutic self assembled monolayers during drug loading and in-vitro drug delivery. In: Transactions of the 31st annual meeting of the Society for Biomaterials, Society for Biomaterials, Pittsburgh, PA, USA; 2006. Abstract no: 327.
269. Goodfellow Corporation, Devon, PA. Iron (Fe). Available from 〈http://www.goodfellow.com/csp/active/gfHome.csp〉 July 2006.
270. Magnesium Elektron, Manchaster, England. "ELEKTRON WE43". Available from 〈http://www.magnesium-elektron.com/data/downloads/DS467WE43.pdf〉 July 2006.
271. US Food and Drug Administration; Center for Devices and Radiological Health."BiodivYsio™AS PC (phosphorylcholine) coated stent delivery system-P000011". Available from 〈http://www.fda.gov/cdrh/mda/docs/p000011.html〉 updated 8 March 2001.
272. US Food and Drug Administration; Center for Devices and Radiological Health.BeStent™ 2 with Discrete Technology™ Over-the-Wire and rapid exchange coronary stent delivery systems-P000022. Available from 〈http://www.fda.gov/cdrh/mda/docs/p000022.html〉 updated 31 January 2001.
273. US Food and Drug Administration, Center for Devices and Radiological Health. NIRflex™ premounted coronary stent system-P020040. Available from 〈http://www.fda.gov/cdrh/mda/docs/p020040.html〉 updated 27 January 2004.
274. US Food and Drug Administration, Center for Devices and Radiological Health. TAXUS™ Express2™ paclitaxel-eluting coronary stent system-P030025. Available from 〈http://www.fda.gov/cdrh/mda/docs/p030025.html〉 updated 9 September 2004.
275. US Food and Drug Administration, Center for Devices and Radiological Health. Boston Scientific Liberte™ Monorail™ and Over-the-Wire coronary stent systems-P040016. Available from 〈http://www.fda.gov/cdrh/mda/docs/p040016.html〉 updated 13 April 2005.
276. US Food and Drug Administration, Center for Devices and Radiological Health. Rithron-XR coronary stent system-P030037. Available from 〈http://www.fda.gov/cdrh/mda/docs/p030037.html〉 updated 23 May 2005.